Levi & Korsinsky is investigating the Board of Directors of NPS
Pharmaceuticals Inc. (“NPS Pharmaceuticals” or “the Company”) (NASDAQGS:
NPSP) for possible breaches of fiduciary duty and other violations of
state law in connection with the sale of the Company to Shire plc.
Sign-up for NPSP INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation of the Board of Directors of NPS Pharmaceuticals Inc. Concerning the Fairness of the Sale of the Company to Shire plc investment picks
Sign-up for NPSP SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches an Investigation of the Board of Directors of NPS Pharmaceuticals Inc. Regarding the Fairness of the Sale of the Company to Shire plc-- NPSP investment picks
Kirby McInerney LLP is investigating potential claims against NPS
Pharmaceuticals, Inc. (“NPS” or the “Company”) (NASDAQ:NPSP) concerning
the proposed acquisition of the Company by Shire plc (“Shire”) (LSE:
SHP) (NASDAQ: SHPG). Under the terms of the merger agreement, NPS
stockholders will receive $46.00 in cash for each share of NPS common
stock they own, valuing the transaction at approximately $5.2 billion.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.